Longeveron Inc. (LGVN)
LGVN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1721484/000119312526110664/0001193125-26-110664-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | LGVN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001721484 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.2M |
| Net income | -$22.7M |
| Operating income | -$23.3M |
| Net margin | -1893.6% |
| Operating margin | -1942.2% |
| Revenue growth | -49.9% |
| Cash | $4.7M |
| Total assets | $10.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 6.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result, there is substantial doubt about the Company's ability to continue as a going concern. 2." | 10-Q 2026-11-12 |
| Cash and burn | $7.2M cash; operating cash flow -$4.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 138,405 (2026-11-10). | Cover page 2026-11-10 |
| Reverse splits, 3 years | 2; latest 1-for-10 on 2026-08-27 | Source 2026-08-27 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-03-25 |
| Auditor | CBIZ CPAs P.C., Hartford, Connecticut, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-03-14 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 3,373,340 shares at the 2026-11-13 price; the latest SEC cover count is 138,405 as of 2026-11-10. One of the two share counts is stale. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $115K | -$6.1M | -$2.7M | $7.2M | No debt tags | $1.2M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $287K | -$6.1M | -$5.7M | $10.1M | No debt tags | $1.2M | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $398K | -$4.7M | -$4.4M | $15.8M | No debt tags | $1.2M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $365K | -$5.4M | -$5.3M | $4.7M | No debt tags | $1.2M | 10-K 2026-03-17 |
| Q3 2025 2025-09-30 | $137K | -$7.2M | -$5.1M | $9.2M | No debt tags | $1.4M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $316K | -$5.0M | -$3.6M | $10.3M | No debt tags | $2.1M | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $381K | -$5.0M | -$4.7M | $14.3M | No debt tags | $2.2M | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $603K | -$4.1M | -$3.4M | $19.2M | No debt tags | $2.4M | 10-K 2026-03-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2026-04-17 |
| Latest annual report | 10-K | 2026-03-17 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-12 |
| Latest proxy DEFINITIVE ADDITIONAL MATERIALS | DEFA14A | 2026-05-20 |
Source: SEC EDGAR submissions feed, 536 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +37.6% |
| 1 month | +15.8% |
| 3 months | -64.3% |
| Year to date | -50.8% |
| 1 year | -63.9% |
| From 52-week high | -78.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMRN | Immuron Limited | $0.8996 | +2.23% | $7.3M |
| CURX | Curanex Pharmaceuticals Inc | $4.63 | -0.11% | $7.3M |
| GTBP | GT Biopharma Inc. | $3.54 | -1.81% | $7.3M |
| UPC | Universe Pharmaceuticals Inc. | $1.48 | -1.99% | $7.4M |
| XCUR | Exicure Inc. | $1.07 | -0.93% | $7.0M |
| MBRX | Moleculin Biotech Inc. | $7.14 | -9.28% | $7.6M |
| TPST | Tempest Therapeutics Inc. | $0.3418 | -10.50% | $6.8M |
| SNGX | Soligenix Inc. | $0.2882 | -10.22% | $6.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier